Tumor mutation burden in biliary tract cancers with ERBB family or DNA damage repair gene mutations. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...

The MASAI trial1 is an important step. Jessie Gommers and colleagues report non-inferiority for interval cancer rate with an artificial intelligence (AI)-supported workflow, alongside higher ...

The European Medicines Agency (EMA) is proposing a new guideline on sponsors’ use of non-inferiority designs to assess the safety and effectiveness of new drugs in clinical trials. The proposal aims ...

The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...

Correspondence to Professor Steven M McPhail, Australian Centre for Health Services Innovation, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia; steven.mcphail{at}qut.edu.au ...

Repros Therapeutics Androxal Shows Noninferiority In Interim Phase 3 Analysis THE WOODLANDS, Texas -- Repros Therapeutics Inc. announced interim results of a U.S. Phase 3 study of Androxalâ„¢, an oral ...

Please provide your email address to receive an email when new articles are posted on . Tapering regimens were linked to significantly higher flare risk among patients in RA remission. The results ...

ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...